Every GLP-1's Boxed Warning Explained: MTC, MEN 2 & Thyroid C-Cell Tumors

Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Rybelsus, and Saxenda all carry the same FDA boxed warning. Here's exactly what it says, what medullary thyroid carcinoma and MEN 2 actually are, who is absolutely contraindicated, and what the rodent studies behind the warning actually showed.

If you've read the prescribing label of any GLP-1 receptor agonist on the U.S. market, you've seen it: a stark warning, set apart in a black box at the very top of the document. It is the FDA's most serious form of labeling — a signal that the agency considers the risk significant enough to require physician attention before the drug is prescribed.

Every currently-marketed GLP-1 medication carries this warning. The wording is essentially identical across all of them. And the language is unambiguous about who should never receive these drugs: anyone with a personal or family history of medullary thyroid carcinoma (MTC), and anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

This is a comprehensive, source-cited breakdown of what that warning actually says, what the underlying conditions are, where the data came from, and what it means in practice for patients and prescribers.

The Verbatim FDA Boxed Warning

The boxed warning text is functionally identical across every GLP-1 receptor agonist with this labeling. Only the drug name changes. Here is the standard structure as it appears in the prescribing information:

Two things are worth pausing on. First: the warning explicitly states that human relevance is unknown — not established, not refuted. Second: the contraindications are absolute. They are not "use with caution" or "consider risks." They are categorical.

Which GLP-1s Carry This Warning?

Every long-acting GLP-1 receptor agonist and dual-agonist currently on the U.S. market carries the boxed warning. This includes both diabetes and weight management indications, and both injectable and oral formulations.

One historical exception is worth noting: the original short-acting formulation of exenatide (Byetta), discontinued in the U.S. in recent years, did not initially carry this boxed warning when introduced in 2005. The longer-acting GLP-1s that followed all do. The pattern aligns with what was found in animal studies: the longer the GLP-1 receptor stimulation, the more pronounced the C-cell effect in rodents.

What Is Medullary Thyroid Carcinoma (MTC)?

Medullary thyroid carcinoma is a rare and distinct form of thyroid cancer. Unlike the more common papillary or follicular thyroid cancers — which arise from the thyroid's hormone-producing follicular cells — MTC originates in parafollicular cells, also known as C-cells. These cells produce calcitonin, a hormone involved in calcium regulation.

MTC accounts for roughly 1–2% of all thyroid cancers in the United States. It behaves differently from other thyroid cancers in important ways: it does not respond to radioactive iodine treatment, it tends to spread to lymph nodes early, and its biology is driven by genetics in a way the more common thyroid cancers are not.

Sporadic vs. Hereditary MTC

About 75% of MTC cases occur sporadically, with no identified inherited cause. The remaining 25% are hereditary — and essentially all hereditary cases are caused by germline mutations in the RET proto-oncogene. These hereditary forms fall under the MEN 2 umbrella, discussed in the next section.

Because of this strong genetic component, current clinical guidelines from the American Thyroid Association recommend that anyone diagnosed with MTC undergo RET genetic testing, regardless of family history. A positive RET mutation finding then triggers cascade testing of first-degree relatives.

Symptoms the FDA Warning Specifically Names

The boxed warning instructs prescribers to counsel patients about specific symptoms of thyroid tumors. These are:

• A mass in the neck — typically painless, often noticed by the patient or during a routine exam
• Dysphagia — difficulty swallowing
• Dyspnea — difficulty breathing or shortness of breath
• Persistent hoarseness — particularly hoarseness that lasts more than a few weeks without obvious cause

Any of these symptoms in a patient on a GLP-1 medication warrants prompt evaluation, including thyroid imaging and, if indicated, calcitonin measurement.

What Is MEN 2?

Multiple Endocrine Neoplasia type 2 is an inherited cancer predisposition syndrome. It is caused by mutations in the RET proto-oncogene, the same gene implicated in hereditary MTC. The inheritance pattern is autosomal dominant — meaning a child of an affected parent has a 50% chance of inheriting the mutation, and a single mutated copy is sufficient to cause the syndrome.

MEN 2 is divided into three clinical subtypes:

Because MEN 2 carries an extremely high lifetime risk of MTC, the diagnosis itself is sufficient to contraindicate GLP-1 therapy — even in a patient who has not yet developed thyroid cancer.

If a first-degree relative has been diagnosed with MTC or MEN 2, the standard of care is to pursue genetic counseling and RET testing before considering any therapy that interacts with thyroid C-cells, including GLP-1 medications.

Where the Warning Came From: The Rodent Data

The boxed warning traces back to preclinical safety studies conducted during the development of liraglutide in the early 2000s. In standard two-year carcinogenicity studies, both rats and mice exposed to clinically relevant doses of liraglutide developed dose- and duration-dependent thyroid C-cell hyperplasia and, in some cases, C-cell adenomas and carcinomas.

Subsequent studies of other long-acting GLP-1s — including exenatide ER, dulaglutide, semaglutide, and tirzepatide — produced similar findings in rodents. The effect appeared consistent across the drug class.

The mechanism is biological: rodent thyroid C-cells express GLP-1 receptors at far higher density than human thyroid C-cells. When activated, these receptors stimulate calcitonin release and, with chronic stimulation, can drive C-cell proliferation. The relevant question — asked at every regulatory review since — is whether the much sparser GLP-1 receptor expression in human C-cells is enough to translate that signal into clinical disease.

The FDA's position has been precautionary. In the absence of evidence resolving the question one way or the other, the agency has consistently required the boxed warning, the contraindications, and patient counseling on every GLP-1 receptor agonist approved since liraglutide.

What About Humans? Reading the Real-World Data

The honest answer is that the human evidence so far does not show a clear MTC signal — but it also doesn't fully exonerate the drug class.

Large cardiovascular outcome trials, originally designed to assess heart safety, have provided some of the longest-running human exposure data for GLP-1s. The LEADER trial of liraglutide enrolled over 9,000 patients followed for a median of 3.8 years. The SUSTAIN-6 and SOUL trials of semaglutide added years of additional exposure data. None of these trials demonstrated a clear excess of MTC or other thyroid cancers attributable to GLP-1 therapy.

Calcitonin elevations have occasionally been observed in patients on GLP-1 therapy, but these elevations have generally been small, non-progressive, and not associated with development of MTC during follow-up. Routine calcitonin monitoring has therefore not been recommended by regulatory or specialty bodies.

One observational study did receive significant attention: a 2023 French nested case-control analysis published in JAMA Internal Medicine reported a possible association between 1–3 years of GLP-1 use and increased thyroid cancer incidence. The study had methodological limitations — including potential surveillance bias, since patients on GLP-1s undergo more medical monitoring overall — and subsequent larger analyses, including studies using UK Biobank and Scandinavian registry data, have not consistently replicated the finding.

The current state of the evidence: no clear human signal for MTC, persistent uncertainty about long-term effects with multi-decade exposure, and a regulatory posture that errs on the side of the warning remaining in place.

Who Is Absolutely Contraindicated

The boxed warning identifies specific populations who should not receive any GLP-1 receptor agonist. A responsible prescriber will screen for each of these before issuing a prescription.

If any of these apply, a prescriber should not initiate GLP-1 therapy. If a telehealth platform issues a prescription without screening for these conditions, that is a meaningful red flag about its clinical standards.

Should You Be Screened Before Starting?

Routine pre-prescription screening for MTC — such as baseline calcitonin testing or thyroid ultrasound for everyone — is not currently recommended by the FDA, the American Thyroid Association, or the American Association of Clinical Endocrinologists. The reason is straightforward: the false-positive rate of calcitonin testing in a low-risk population is too high, generating more anxiety, follow-up procedures, and harm than benefit.

What is recommended is a thorough clinical history. A competent prescriber should ask, before issuing your first GLP-1 prescription:

• Have you ever been diagnosed with any thyroid cancer?
• Has anyone in your immediate family been diagnosed with MTC or any thyroid cancer?
• Has anyone in your family been diagnosed with MEN 2 or had a pheochromocytoma?
• Have you ever had genetic testing related to RET mutations?
• Do you have any current symptoms — neck mass, persistent hoarseness, swallowing or breathing difficulty?

If the answer to any of these questions is yes, or even uncertain, the appropriate next step is referral to endocrinology before — not after — starting a GLP-1.

What This Means When Choosing a Provider

The boxed warning isn't just a regulatory artifact. It's a screen on the prescribing process itself. Providers who take the warning seriously build family-history questions into their intake, document the answers, and decline to prescribe when contraindications surface. Providers who don't may issue prescriptions to patients who shouldn't be receiving them.

For patients prioritizing brand-name FDA-approved GLP-1 medications and a thorough clinical intake, a few telehealth platforms stand out:

Symptoms That Warrant Immediate Evaluation

If you are on a GLP-1 medication and develop any of the symptoms named in the boxed warning, contact your prescriber promptly. These symptoms can have many causes — most of them benign — but they should be investigated rather than ignored.

Initial workup typically includes a thyroid ultrasound and, if a nodule is found, fine-needle aspiration with calcitonin measurement. The vast majority of investigations turn out to be unrelated to MTC — but the cost of investigating is small compared to the cost of missing a diagnosis.

What This Means for You

The boxed warning on every GLP-1 medication exists because of unresolved scientific uncertainty, not because of demonstrated harm in humans. For most patients, the benefits of GLP-1 therapy — meaningful and durable weight loss, improved glycemic control, cardiovascular protection, sleep apnea improvement, and an expanding list of other benefits — substantially outweigh the theoretical risk.

But the contraindications are absolute. If you have a personal or family history of MTC, or any form of MEN 2, GLP-1 therapy is off the table — at least until and unless future evidence changes the regulatory position.

For everyone else, the practical takeaway is straightforward: know your family medical history, share it honestly with your prescriber, and choose a provider whose intake process treats the boxed warning as a real screen rather than a formality.

Frequently Asked Questions

Has the FDA ever considered removing the boxed warning?

The FDA has periodically reviewed the warning in light of accumulating human safety data, but has consistently kept it in place. The agency's position has been that without a clear mechanistic explanation for why human C-cells would be immune to the effect seen in rodents, the precautionary warning is appropriate.

Does the warning apply to compounded versions of semaglutide and tirzepatide?

Compounded medications are not FDA-approved and therefore are not subject to FDA labeling requirements. However, the underlying active ingredient is the same, so the same biological concerns apply. Reputable compounding pharmacies and the providers who prescribe their products generally apply the same contraindications voluntarily.

If I had thyroid cancer that wasn't MTC, can I still take a GLP-1?

The contraindication specifically names medullary thyroid carcinoma. Other thyroid cancers — papillary, follicular, anaplastic — arise from different cells and are not subject to the contraindication. That said, this is a conversation to have with your endocrinologist and prescriber, not a self-determination.

What if I'm not sure about my family history?

Tell your prescriber that. Uncertainty in family history is itself information. If a relative had "thyroid cancer" but the type wasn't documented, your prescriber can help you decide whether further investigation — or genetic counseling — is warranted before starting therapy.

Are calcitonin levels routinely checked on GLP-1 therapy?

No. Routine calcitonin monitoring is not recommended by the FDA, the American Thyroid Association, or any major endocrine society. The test's specificity is too low for population screening. Calcitonin is reserved for patients with concerning symptoms or thyroid nodules identified on imaging.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, sourcing standards, or provider selection. This article is informational only and does not constitute medical advice. Always consult a licensed clinician about your personal medical situation.